EMBC trades 43.3% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EMBC achieves its forward estimates and maintains a stable P/E multiple of 2.2x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Embecta Corp. (EMBC) has a Wall Street consensus price target of $5.00, based on estimates from 4 covering analysts. With the stock currently trading at $3.49, this represents a potential upside of +43.3%. The company has a market capitalization of $207M.
Analyst price targets range from a low of $5.00 to a high of $5.00, representing a 0% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 0 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 2 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, EMBC trades at a trailing P/E of 2.2x and forward P/E of 2.2x. Analysts expect EPS to grow -16.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $12.42, with bear and bull scenarios of $7.82 and $16.36 respectively. Model confidence stands at 46/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
UTMDUtah Medical Products, Inc. | $236M | $73.97 | — | — | — | 11.8x | — |
LFUSLittelfuse, Inc. | $11.4B | $452.36 | $478.75 | +5.8% | Buy | 31.1x | 12 |
NVCRNovoCure Limited | $1.8B | $15.43 | $33.00 | +113.9% | Buy | — | 15 |
ITGRInteger Holdings Corporation | $3.2B | $93.89 | $108.00 | +15.0% | Buy | 15.4x | 15 |
MMSIMerit Medical Systems, Inc. | $4.3B | $71.73 | $94.20 | +31.3% | Buy | 17.6x | 14 |
BDXBecton, Dickinson and Company | $56.5B | $155.92 | $174.81 | +12.1% | Hold | 12.4x | 34 |
NVONovo Nordisk A/S | $213.4B | $48.02 | $45.00 | -6.3% | Buy | 2.2x | 39 |
DXCMDexCom, Inc. | $27.1B | $70.14 | $83.80 | +19.5% | Buy | 27.1x | 52 |
PODDInsulet Corporation | $11.1B | $158.25 | $220.79 | +39.5% | Buy | 24.4x | 50 |
TNDMTandem Diabetes Care, Inc. | $1.1B | $16.24 | $29.95 | +84.4% | Buy | — | 39 |
Quick answers to the most common questions about buying EMBC stock.
The consensus Wall Street price target for EMBC is $5, representing 43.3% upside from the current price of $3.49. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
EMBC has a consensus rating of "Hold" based on 4 Wall Street analysts. The rating breakdown is leaning bearish, with 2 Sell/Strong Sell ratings. The consensus 12-month price target of $5 implies 43.3% upside from current levels.
With a forward P/E of 2.1906x, EMBC trades at a relatively low valuation. The consensus target of $5 implies 43.3% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $5 for EMBC, while the most conservative target is $5. The consensus of $5 represents the median expectation. Our quantitative valuation model projects a bull case target of $16 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
EMBC is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 2 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EMBC stock forecast based on 4 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $5 (bear case) to $5 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $12, with bear/bull scenarios of $8/$16.
Our quantitative valuation model calculates EMBC's fair value at $12 (base case), with a bear case of $8 and bull case of $16. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.
EMBC trades at a forward P/E ratio of 2.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 2.2x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on EMBC, with a "Hold" consensus rating and $5 price target (43.3% upside). 0 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EMBC analyst price targets range from $5 to $5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground. Our model's $8-$16 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.